• Explore /
  • Poster
  • / A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.

Abstract Poster

Authors

null

Jiayu Wang

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Jiayu Wang , Binghe Xu , Tao Sun , Quchang Ouyang , Yiqun Han , Qing Li , Pin Zhang , Fei Ma , Yang Luo , Ying Fan , Ruigang Cai , Qiao Li , Bo Lan , Hongnan Mo , Jiani Wang , Yiqun Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT03855358

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1074)

DOI

10.1200/JCO.2021.39.15_suppl.1074

Abstract #

1074

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Pei Dong

First Author: Akshit Chitkara

First Author: Qin Xu

First Author: Qin Xu